[A]: Heyï¼Œå…³äº'æœ€è¿‘æœ‰æ²¡æœ‰ä»€ä¹ˆè®©ä½ å¾ˆexcitedçš„upcoming techï¼Ÿ'è¿™ä¸ªè¯é¢˜ï¼Œä½ æ€ä¹ˆæƒ³çš„ï¼Ÿ
[B]: å“ˆï¼Œè¯´åˆ°excitingçš„techï¼Œæœ€è¿‘ç¡®å®æœ‰ä¸ªdealè®©æˆ‘å¾ˆæ„Ÿå…´è¶£~ æ˜¯å®¶åšquantum computingçš„startupï¼Œä»–ä»¬çš„algorithmåœ¨portfolio optimizationæ–¹é¢è¡¨ç°ç›¸å½“impressiveã€‚ä¸è¿‡ä½ çŸ¥é“çš„ï¼Œè¿™ç±»deep techéœ€è¦æ›´è°¨æ…çš„due diligence ğŸ˜Š
[A]: å“‡~ quantum computingç¡®å®å¾ˆfascinatingï¼ä¸è¿‡ä½œä¸ºåŒ»ç–—æ³•å¾‹é¡¾é—®ï¼Œæˆ‘æ›´å…³æ³¨healthcareé¢†åŸŸçš„innovationå‘¢ã€‚æœ€è¿‘æœ‰ä¸ªç”¨AIè¾…åŠ©diagnosisçš„caseå°±è®©æˆ‘å¾ˆexcitedï¼Œä½†åŒæ—¶ä¹Ÿæ¶‰åŠåˆ°å¾ˆå¤šdata privacyå’Œmedical ethicsçš„issues ğŸ¤”
[B]: Interesting point~ åœ¨healthcare teché¢†åŸŸï¼Œæˆ‘ä»¬fundæœ€è¿‘ä¹Ÿåœ¨çœ‹å‡ ä¸ªAI+diagnosisçš„targetsã€‚è¯´å®è¯ï¼Œè¿™äº›é¡¹ç›®çš„valuationç°åœ¨æœ‰ç‚¹bubbleçš„è¿¹è±¡ï¼Œä½†long-term growth potentialç¡®å®å¾ˆå¤§ã€‚è¯´åˆ°data privacy...  è¿™ç¡®å®æ˜¯investorsæœ€å…³æ³¨çš„risk factorä¹‹ä¸€
[A]: è®©æˆ‘æƒ³æƒ³...æ ¹æ®Article 35 of GDPRçš„è§„å®šï¼Œhealth dataå±äºspecial category dataå‘¢ã€‚æˆ‘æœ€è¿‘å¤„ç†çš„å‡ ä¸ªcaseéƒ½æ¶‰åŠåˆ°patient consentå’Œdata anonymizationçš„é—®é¢˜ã€‚ä¸è¿‡è¯´åˆ°valuationï¼ŒåŒ»ç–—AIç¡®å®éœ€è¦æ›´ä¸¥æ ¼çš„clinical validation ğŸµ
[B]: Exactlyï¼è¿™å°±æ˜¯ä¸ºä»€ä¹ˆæˆ‘ä»¬åšDDæ—¶ç‰¹åˆ«çœ‹é‡ä»–ä»¬çš„clinical trial resultså’Œregulatory compliance recordã€‚ é¡ºä¾¿é—®ä¸€å¥ï¼Œä½ å¯¹FDAæœ€æ–°çš„AI/ML-based SaMD guidance frameworkæœ‰ä»€ä¹ˆçœ‹æ³•ï¼Ÿè¿™å¯¹valuationä¼šæœ‰significant impact
[A]: å•Šï¼Œè¿™ä¸ªframeworkç¡®å®å¾ˆå…³é”®ï¼æ ¹æ®æœ€æ–°çš„guidelineï¼ŒSaMDäº§å“éœ€è¦æ›´ä¸¥æ ¼çš„real-world performance monitoringã€‚æˆ‘ä¸Šå‘¨åˆšå¸®ä¸€ä¸ªclient reviewäº†ä»–ä»¬çš„post-market surveillance planï¼Œè¿™ç›´æ¥å…³ç³»åˆ°product lifecycle managementå‘¢~ ä¸è¿‡è¯è¯´å›æ¥ï¼Œè¿™äº›regulatory requirementsä¹Ÿä¼šå¢åŠ time to marketçš„æˆæœ¬å“¦ ğŸ˜Š
[B]: Spot onï¼æ‰€ä»¥æˆ‘ä»¬ç°åœ¨ç”¨discounted cash flow modelæ—¶ï¼Œéƒ½ä¼šæŠŠregulatory timeline delay risk factorè€ƒè™‘è¿›å»ã€‚ è¯´åˆ°è¿™ä¸ªï¼Œæˆ‘ä»¬æœ€è¿‘portfolioé‡Œæœ‰ä¸ªhealthtech startupå°±å› ä¸ºEU MDRçš„é—®é¢˜delayäº†Series C round... çœŸæ˜¯painful lesson learned
[A]: Oh no...EU MDRçš„transition periodç¡®å®è®©å¾ˆå¤šmedtech companieså¤´ç–¼å‘¢ï¼æˆ‘å»ºè®®ä½ ä¸‹æ¬¡åšDDæ—¶é‡ç‚¹å…³æ³¨ä»–ä»¬çš„quality management systemå’Œtechnical documentationã€‚æœ€è¿‘å¤„ç†çš„å‡ ä¸ªMDR-related caseéƒ½è¯æ˜ï¼Œearly preparation is the key~ è¦ä¸è¦æˆ‘shareä¸€äº›best practicesç»™ä½ ï¼Ÿ ğŸ¤—
[B]: That would be super helpfulï¼ æˆ‘ä»¬æ­£åœ¨evaluateä¸€ä¸ªGerman medtechçš„dealï¼Œä»–ä»¬çš„QMSç¡®å®éœ€è¦æ›´thoroughçš„reviewã€‚By the wayï¼Œä¸‹å‘¨ä¸‰æˆ‘è¦å»æ…•å°¼é»‘meetä»–ä»¬çš„management teamï¼Œå¦‚æœä½ æœ‰ç©ºå¯ä»¥join usåšregulatory due diligenceï¼Ÿå½“ç„¶ï¼Œfeeæ–¹é¢æˆ‘ä»¬å¯ä»¥æŒ‰hourly rateæ¥ç®—~
[A]: è®©æˆ‘checkä¸‹calendar...å•Šï¼Œä¸‹å‘¨ä¸‰åˆšå¥½æœ‰ä¸ªclient meetingï¼Œä¸è¿‡å¯ä»¥reschedule~ æ…•å°¼é»‘çš„è¯ï¼Œæˆ‘å»ºè®®æˆ‘ä»¬æå‰å‡†å¤‡ä¸€ä¸ªchecklistï¼Œé‡ç‚¹çœ‹ä»–ä»¬çš„clinical evaluation reportå’Œpost-market clinical follow-up planã€‚æ ¹æ®Article 61 of MDRï¼Œè¿™äº›éƒ½æ˜¯essential requirementså‘¢ï¼Shall we set up a quick call tomorrow to alignï¼Ÿ ğŸ˜Š
[B]: Perfectï¼Let's do a Zoom call tomorrow 3pm CETï¼Ÿæˆ‘ä¼šè®©assistantå‘ä½ ä¸€ä¸ªpreliminary DD checklistï¼Œæˆ‘ä»¬å¯ä»¥åœ¨æ­¤åŸºç¡€ä¸Šrefineã€‚ å¯¹äº†ï¼Œä½ ä¸Šæ¬¡æåˆ°çš„medical device cybersecurity guidanceä¹Ÿå¾ˆrelevantï¼Œè®°å¾—bring that up during discussion~
[A]: Got itï¼3pm CET works perfectly for me~ æˆ‘ä¼šå‡†å¤‡å¥½cybersecurityç›¸å…³çš„materialsï¼Œç‰¹åˆ«æ˜¯å…³äºIEC 62304 complianceçš„éƒ¨åˆ†ã€‚è¿™ä¸ªstandardå¯¹software development lifecycleçš„è¦æ±‚ç‰¹åˆ«ä¸¥æ ¼å‘¢ï¼Looking forward to our collaboration ğŸ¤—
[B]: Greatï¼See you tomorrow thenã€‚ é¡ºä¾¿è¯´ä¸€å¥ï¼Œå¦‚æœä½ å¯¹healthtech investmentæ„Ÿå…´è¶£ï¼Œæˆ‘ä»¬ä¸‹ä¸ªæœˆåœ¨è‹é»ä¸–æœ‰ä¸ªexclusive summitï¼Œå¯ä»¥put you on the guest listã€‚Always good to expand professional network in this space~
[A]: That sounds amazingï¼è‹é»ä¸–çš„summitä¸€ç›´å¾ˆæœ‰reputationå‘¢~ ä½œä¸ºåŒ»ç–—æ³•å¾‹é¡¾é—®ï¼Œnetworkingç¡®å®å¾ˆé‡è¦ï¼Œç‰¹åˆ«æ˜¯èƒ½connect with industry leaderså’Œregulatorsã€‚Count me inï¼ä¸è¿‡æˆ‘å¾—å…ˆcheckä¸‹æœ‰æ²¡æœ‰conflict of interest with my current clients ğŸ˜Š
[B]: Smart moveï¼Professional ethics always come firstã€‚ æˆ‘ä¼šè®©teamå‘ä½ event detailså’Œspeaker listï¼Œä½ å¯ä»¥reviewåå†confirmã€‚Anywayï¼Œtomorrow's callæˆ‘ä»¬å…ˆæŠŠGerman dealçš„regulatory risksæ¢³ç†æ¸…æ¥š~ Cheersï¼
[A]: Cheers to thatï¼æ˜å¤©æˆ‘ä¼šbring my laptopï¼Œå‡†å¤‡å¥½åšdetailed notes~ è®°å¾—æé†’æˆ‘shareé‚£ä¸ªå…³äºMDR Article 120 transitional provisionsçš„analysiså“¦ï¼Have a great evening & see you tomorrow at 3pm sharp ğŸµ
[B]: Will doï¼Enjoy your evening too~  æ˜å¤©è§ï¼
[A]: æ˜å¤©è§ï¼è®°å¾—å‡†å¤‡å¥½ä½ çš„questions listå“¦~ é¡ºä¾¿è¯´ä¸€å¥ï¼Œæˆ‘æœ€è¿‘å‘ç°ä¸€å®¶å¾ˆæ£’çš„jazz barå°±åœ¨æ…•å°¼é»‘ï¼Œä¹Ÿè®¸after our meetingæˆ‘ä»¬å¯ä»¥å»æ”¾æ¾ä¸€ä¸‹ï¼ŸMusic always helps with deal fatigue ğŸ˜‰ğŸ¶
[B]: Hahaï¼Œdeal fatigueç¡®å®æ˜¯æˆ‘ä»¬è¿™è¡Œçš„occupational hazardå•Šï¼ é‚£å®¶jazz baræ˜¯ä¸æ˜¯åœ¨MaxvorstadtåŒºï¼Ÿæˆ‘ä¸Šæ¬¡å»æ…•å°¼é»‘å°±å¬è¯´é‚£é‡Œæœ‰hidden gemsã€‚ä¸è¿‡è¿™æ¬¡scheduleæœ‰ç‚¹tightï¼Œmaybe next round~ ç°åœ¨è¿˜æ˜¯focus onæ˜å¤©çš„DD checklistæ¯”è¾ƒwise ğŸ˜Š